Published in Clin Microbiol Rev on April 01, 1998
Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev (2007) 15.66
Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev (1999) 12.90
Current and emerging azole antifungal agents. Clin Microbiol Rev (1999) 5.70
Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev (1999) 5.51
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2001) 4.05
Candida biofilms: an update. Eukaryot Cell (2005) 3.58
Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother (2002) 3.38
In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother (2002) 3.36
Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol (2002) 3.27
Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun (2004) 3.21
Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother (2006) 3.19
In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother (1998) 3.06
The ins and outs of DNA fingerprinting the infectious fungi. Clin Microbiol Rev (2000) 2.95
Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother (1998) 2.93
In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother (2001) 2.84
Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol (2012) 2.82
Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J (2002) 2.81
Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. Antimicrob Agents Chemother (2006) 2.68
Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother (2001) 2.65
Evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol (2000) 2.58
Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev (2004) 2.45
Efflux-mediated antifungal drug resistance. Clin Microbiol Rev (2009) 2.44
Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev (2006) 2.39
The trailing end point phenotype in antifungal susceptibility testing is pH dependent. Antimicrob Agents Chemother (1999) 2.26
Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell (2007) 2.25
Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother (1998) 2.15
In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol (1999) 2.10
A sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. PLoS Pathog (2008) 2.09
Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. PLoS Genet (2009) 2.07
Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother (2003) 1.98
The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog (2007) 1.94
Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev (2011) 1.90
Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol Microbiol (2008) 1.90
Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol (2013) 1.88
Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot Cell (2004) 1.87
In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother (2003) 1.85
Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother (2003) 1.80
Population genomics of drug resistance in Candida albicans. Proc Natl Acad Sci U S A (2002) 1.76
Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. Antimicrob Agents Chemother (2005) 1.76
In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol (2003) 1.75
Specific chromosome alterations in fluconazole-resistant mutants of Candida albicans. J Bacteriol (1999) 1.73
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell (2008) 1.73
Rapid identification of Candida albicans and other human pathogenic yeasts by using short oligonucleotides in a PCR. J Clin Microbiol (1998) 1.72
A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. Eukaryot Cell (2008) 1.67
In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol (2002) 1.64
PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. PLoS Pathog (2010) 1.63
Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol (2001) 1.63
In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob Agents Chemother (2004) 1.62
Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob Agents Chemother (2001) 1.58
Functional characterization of the Chlamydomonas reinhardtii ERG3 ortholog, a gene involved in the biosynthesis of ergosterol. PLoS One (2010) 1.56
Genomewide location analysis of Candida albicans Upc2p, a regulator of sterol metabolism and azole drug resistance. Eukaryot Cell (2008) 1.56
Single-nucleotide polymorphisms (SNPs) in human beta-defensin 1: high-throughput SNP assays and association with Candida carriage in type I diabetics and nondiabetic controls. J Clin Microbiol (2003) 1.55
Functional expression of Candida albicans drug efflux pump Cdr1p in a Saccharomyces cerevisiae strain deficient in membrane transporters. Antimicrob Agents Chemother (2001) 1.54
Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J Clin Microbiol (2003) 1.54
Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation. Antimicrob Agents Chemother (2002) 1.51
Clonal and spontaneous origins of fluconazole resistance in Candida albicans. J Clin Microbiol (2000) 1.50
Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob Agents Chemother (2004) 1.49
Genome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates. Antimicrob Agents Chemother (2003) 1.49
Flucytosine resistance is restricted to a single genetic clade of Candida albicans. Antimicrob Agents Chemother (2004) 1.49
Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother (2002) 1.46
Reversal of fluconazole resistance by sulfated sterols from the marine sponge Topsentia sp. J Nat Prod (2009) 1.46
Quantitative analysis of the relative transcript levels of ABC transporter Atr genes in Aspergillus nidulans by real-time reverse transcription-PCR assay. Appl Environ Microbiol (2002) 1.44
Transcriptional analyses of antifungal drug resistance in Candida albicans. Antimicrob Agents Chemother (2000) 1.44
Antifungal resistance and new strategies to control fungal infections. Int J Microbiol (2011) 1.44
Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (1999) 1.43
Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Agents Chemother (2000) 1.42
Expressed sequence tag analysis of the human pathogen Paracoccidioides brasiliensis yeast phase: identification of putative homologues of Candida albicans virulence and pathogenicity genes. Eukaryot Cell (2003) 1.40
Multilocus genotypes and DNA fingerprints Do not predict variation in azole resistance among clinical isolates of Candida albicans. Antimicrob Agents Chemother (1999) 1.40
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. Antimicrob Agents Chemother (2010) 1.39
Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrob Agents Chemother (1999) 1.38
In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry. Antimicrob Agents Chemother (2002) 1.38
Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. Antimicrob Agents Chemother (2001) 1.37
Drug susceptibilities of yeast cells are affected by membrane lipid composition. Antimicrob Agents Chemother (2002) 1.36
Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5. Antimicrob Agents Chemother (2001) 1.36
Genome-wide expression and location analyses of the Candida albicans Tac1p regulon. Eukaryot Cell (2007) 1.35
Characterization of three classes of membrane proteins involved in fungal azole resistance by functional hyperexpression in Saccharomyces cerevisiae. Eukaryot Cell (2007) 1.35
Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative. Antimicrob Agents Chemother (2004) 1.34
Rapid identification of candida species by TaqMan PCR. J Clin Pathol (2001) 1.33
The Candida albicans lanosterol 14-alpha-demethylase (ERG11) gene promoter is maximally induced after prolonged growth with antifungal drugs. Antimicrob Agents Chemother (2004) 1.33
Efflux in fungi: la pièce de résistance. PLoS Pathog (2009) 1.33
Transcriptome analysis of Aspergillus fumigatus exposed to voriconazole. Curr Genet (2006) 1.32
Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob Agents Chemother (2005) 1.28
Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob Agents Chemother (2000) 1.28
Tetracycline alters drug susceptibility in Candida albicans and other pathogenic fungi. Microbiology (2008) 1.28
Safety of intravitreal voriconazole: electroretinographic and histopathologic studies. Trans Am Ophthalmol Soc (2003) 1.28
Critical annotations to the use of azole antifungals for plant protection. Antimicrob Agents Chemother (2001) 1.26
Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans. Antimicrob Agents Chemother (2011) 1.24
Induction of resistance to azole drugs in Trypanosoma cruzi. Antimicrob Agents Chemother (1998) 1.23
Overexpression of Erg11p by the regulatable GAL1 promoter confers fluconazole resistance in Saccharomyces cerevisiae. Antimicrob Agents Chemother (1999) 1.23
Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2010) 1.22
Ras pathway signaling accelerates programmed cell death in the pathogenic fungus Candida albicans. Proc Natl Acad Sci U S A (2006) 1.22
Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob Agents Chemother (2006) 1.22
A small subpopulation of blastospores in candida albicans biofilms exhibit resistance to amphotericin B associated with differential regulation of ergosterol and beta-1,6-glucan pathway genes. Antimicrob Agents Chemother (2006) 1.22
Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Clin Microbiol Rev (1999) 1.21
Antifungal drug resistance of oral fungi. Odontology (2010) 1.21
Recent insights into Candida albicans biofilm resistance mechanisms. Curr Genet (2013) 1.20
Two N-myristoyltransferase isozymes play unique roles in protein myristoylation, proliferation, and apoptosis. Mol Cancer Res (2005) 1.20
Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides. Antimicrob Agents Chemother (1999) 1.20
Evolution of microbial pathogens. Philos Trans R Soc Lond B Biol Sci (2000) 1.20
Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med (1991) 12.09
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med (1994) 9.11
Resistance of Candida species to fluconazole. Antimicrob Agents Chemother (1995) 9.04
Proton-dependent multidrug efflux systems. Microbiol Rev (1996) 8.81
Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother (1995) 7.44
Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods. Antimicrob Agents Chemother (1987) 7.33
A major superfamily of transmembrane facilitators that catalyse uniport, symport and antiport. Trends Biochem Sci (1993) 7.14
Computer-assisted methods for assessing strain relatedness in Candida albicans by fingerprinting with the moderately repetitive sequence Ca3. J Clin Microbiol (1990) 6.57
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med (1996) 6.49
A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med (1992) 6.06
Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother (1997) 5.66
Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis (1994) 5.44
Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology (1997) 5.22
Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother (1986) 4.97
Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother (1998) 4.95
Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother (1998) 4.93
Putative virulence factors of Candida albicans. Annu Rev Microbiol (1991) 4.85
Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother (1997) 4.75
Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol (1994) 4.27
Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med (1985) 4.25
Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother (1996) 4.24
Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother (1993) 4.04
Oral azole drugs as systemic antifungal therapy. N Engl J Med (1994) 3.96
Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr Genet (1995) 3.85
Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother (1994) 3.82
Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother (1979) 3.79
Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother (1993) 3.79
Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother (1997) 3.78
High-frequency switching in Candida albicans. Clin Microbiol Rev (1992) 3.70
Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol (1994) 3.64
The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans. Antimicrob Agents Chemother (1997) 3.56
Molecular mechanisms of drug resistance in fungi. Trends Microbiol (1994) 3.55
Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole. J Clin Microbiol (1996) 3.42
Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother (1997) 3.40
Cryptococcal infections in patients with acquired immune deficiency syndrome. Am J Med (1986) 3.34
Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother (1993) 3.32
Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med (1994) 3.32
Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis (1997) 3.27
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother (1993) 3.25
Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother (1992) 3.23
Switching of Candida albicans during successive episodes of recurrent vaginitis. J Clin Microbiol (1989) 3.10
Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother (1995) 3.06
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol (1990) 2.99
Genetic similarity and maintenance of Candida albicans strains from a group of AIDS patients, demonstrated by DNA fingerprinting. J Clin Microbiol (1992) 2.98
The yeast Candida albicans has a clonal mode of reproduction in a population of infected human immunodeficiency virus-positive patients. Proc Natl Acad Sci U S A (1993) 2.94
Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother (1996) 2.84
Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother (1995) 2.83
Colonizing populations of Candida albicans are clonal in origin but undergo microevolution through C1 fragment reorganization as demonstrated by DNA fingerprinting and C1 sequencing. J Clin Microbiol (1995) 2.74
Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett (1997) 2.72
Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg (1994) 2.68
Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol Gen Genet (1991) 2.67
Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol. Biochem Biophys Res Commun (1995) 2.66
The mutation T315A in Candida albicans sterol 14alpha-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J Biol Chem (1997) 2.63
Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob Agents Chemother (1995) 2.62
Mitotic recombination in Candida albicans: recessive lethal alleles linked to a gene required for methionine biosynthesis. Mol Gen Genet (1982) 2.59
Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med (1988) 2.44
Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother (1997) 2.43
Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet (1989) 2.41
Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med (1983) 2.35
Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis (1993) 2.35
Isolation of the gene for cytochrome P450L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans. Gene (1988) 2.34
Fatal septicemia due to amphotericin B-resistant Candida lusitaniae. J Clin Microbiol (1983) 2.34
Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol (1994) 2.32
Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob Agents Chemother (1995) 2.32
Resistance of Candida albicans to azole antifungal agents. Biochem Soc Trans (1993) 2.28
Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother (1997) 2.27
Nucleotide sequence of cytochrome P450 L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans. Nucleic Acids Res (1989) 2.27
In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother (1997) 2.27
Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene. Antimicrob Agents Chemother (1994) 2.23
High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother (1994) 2.21
Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis (1995) 2.20
Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol (1996) 2.19
Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett (1997) 2.15
Rapid detection and identification of Candida albicans and Torulopsis (Candida) glabrata in clinical specimens by species-specific nested PCR amplification of a cytochrome P-450 lanosterol-alpha-demethylase (L1A1) gene fragment. J Clin Microbiol (1994) 2.15
The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans. J Gen Microbiol (1986) 2.08
Inhibition of sterol biosynthesis in Candida albicans by imidazole-containing antifungals. J Gen Microbiol (1980) 2.08
Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol (1993) 2.06
Defective sterol C5-6 desaturation and azole resistance: a new hypothesis for the mode of action of azole antifungals. Biochem Biophys Res Commun (1989) 2.02
Disseminated candidiasis due to amphotericin B-resistant Candida albicans. J Infect Dis (1992) 2.01
Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis (1997) 2.00
Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis (1996) 1.99
Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol (1992) 1.97
Fluconazole-resistant candidosis in an HIV cohort. AIDS (1994) 1.95
Reduced azole susceptibility of oral isolates of Candida albicans from HIV-positive patients and a derivative exhibiting colony morphology variation. J Gen Microbiol (1992) 1.94
Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance. Antimicrob Agents Chemother (1996) 1.89
Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med (1994) 1.87
Sterol synthesis and viability of erg11 (cytochrome P450 lanosterol demethylase) mutations in Saccharomyces cerevisiae and Candida albicans. Lipids (1993) 1.87
High-frequency phenotypic switching in Candida albicans. Trends Genet (1993) 1.86
Genetic similarity of Candida albicans strains from vaginitis patients and their partners. J Clin Microbiol (1993) 1.85
Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet (1996) 1.85
Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis (1997) 1.84
Multidrug resistance in Candida albicans: disruption of the BENr gene. Antimicrob Agents Chemother (1995) 1.84
Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii. Ann Intern Med (1985) 1.84
Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother (1993) 1.83
Multiple regulatory elements control expression of the gene encoding the Saccharomyces cerevisiae cytochrome P450, lanosterol 14 alpha-demethylase (ERG11). J Biol Chem (1992) 1.80
Anti-Candida drugs--the biochemical basis for their activity. Crit Rev Microbiol (1987) 1.76
Effects of itraconazole on cytochrome P-450-dependent sterol 14 alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans. Antimicrob Agents Chemother (1993) 1.72
AP1-mediated multidrug resistance in Saccharomyces cerevisiae requires FLR1 encoding a transporter of the major facilitator superfamily. J Biol Chem (1997) 1.72
Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis (1992) 1.71
Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol (1997) 5.86
Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis (1997) 3.67
Panfungal PCR assay for detection of fungal infection in human blood specimens. J Clin Microbiol (1998) 2.92
Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis (1998) 2.78
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med (1990) 2.66
Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother (2006) 2.65
Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis (1998) 2.61
Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis (2000) 2.59
Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol (1997) 2.49
Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol (2005) 2.29
Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis (1995) 2.20
Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother (1998) 2.15
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood (1992) 2.14
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 2.04
Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med (1993) 2.01
Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med (1986) 1.99
Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis (2010) 1.88
Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation (1997) 1.84
Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis (1997) 1.84
Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med (1993) 1.84
Neutrophil transendothelial migration is independent of tight junctions and occurs preferentially at tricellular corners. J Immunol (1997) 1.84
Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood (1992) 1.83
Factors influencing detection of quantitative cytomegalovirus antigenemia. J Clin Microbiol (1994) 1.81
Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med (1988) 1.72
Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood (1999) 1.72
Comparison of six extraction techniques for isolation of DNA from filamentous fungi. Med Mycol (1998) 1.63
Women and the future of academic pediatrics. J Pediatr (1990) 1.51
Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology (1994) 1.51
Analysis of tight junctions during neutrophil transendothelial migration. J Cell Sci (2000) 1.47
Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clin Infect Dis (1996) 1.43
Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia. J Infect Dis (1998) 1.42
Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis (2001) 1.39
Comparison of three methodologies for the determination of pulmonary fungal burden in experimental murine aspergillosis. Clin Microbiol Infect (2006) 1.36
Rapid detection of cytomegalovirus pulmonary infection by bronchoalveolar lavage and centrifugation culture. Ann Intern Med (1988) 1.31
Nocardiosis after bone marrow transplantation: a retrospective study. Clin Infect Dis (1997) 1.27
Bordetella bronchiseptica pneumonia and bacteremia following bone marrow transplantation. J Clin Microbiol (1992) 1.24
Neosartorya udagawae (Aspergillus udagawae), an emerging agent of aspergillosis: how different is it from Aspergillus fumigatus? J Clin Microbiol (2009) 1.23
Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood (1997) 1.23
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting analysis of smooth-lipopolysaccharide heterogeneity among Brucella biovars related to A and M specificities. J Clin Microbiol (1990) 1.18
Fungal infections in patients undergoing blood and marrow transplantation. Transpl Infect Dis (1999) 1.17
Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis (2001) 1.16
Brain abscess following marrow transplantation: experience at the Fred Hutchinson Cancer Research Center, 1984-1992. Clin Infect Dis (1994) 1.14
Human endothelial cell response to gram-negative lipopolysaccharide assessed with cDNA microarrays. Am J Physiol Cell Physiol (2001) 1.11
P-selectin mediates neutrophil adhesion to endothelial cell borders. J Leukoc Biol (1999) 1.10
Cytomegalovirus disease occurring before engraftment in marrow transplant recipients. Clin Infect Dis (1997) 1.08
Candida glabrata sepsis secondary to oral colonization in bone marrow transplantation. Med Mycol (2004) 1.07
Experimental demonstration of an antigenic relationship between Leptospira and equine cornea. Vet Immunol Immunopathol (1985) 1.07
Tears and aqueous humor from horses inoculated with Leptospira contain antibodies which bind to cornea. Vet Immunol Immunopathol (1987) 1.06
Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis (1997) 1.02
Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. J Infect Dis (1996) 0.99
Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect (2013) 0.99
Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Transpl Infect Dis (2013) 0.99
Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Antimicrob Agents Chemother (1996) 0.98
Monoclonal antibodies to Brucella rough lipopolysaccharide: characterization and evaluation of their protective effect against B. abortus. Res Microbiol (1994) 0.98
Use of bone marrow fibroblasts to prepare targets for an HLA restricted-cytotoxicity assay system. J Clin Microbiol (1984) 0.97
Summary of the International Consensus Symposium on Advances in the Diagnosis, Treatment and Prophylaxis and Cytomegalovirus Infection. Antiviral Res (1996) 0.96
Identification and characterization of Brucella ovis immunogenic proteins using two-dimensional electrophoresis and immunoblotting. Electrophoresis (1997) 0.95
Hepatitis due to herpes simplex virus in marrow-transplant recipients. Clin Infect Dis (1992) 0.95
Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis (1997) 0.94
Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET). Transpl Infect Dis (2014) 0.93
The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore) (1998) 0.91
Donor-derived organ transplant transmission of coccidioidomycosis. Transpl Infect Dis (2011) 0.91
Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2001) 0.91
Central nervous system involvement in cryptococcal infection in individuals after solid organ transplantation or with AIDS. Transpl Infect Dis (2009) 0.90
Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis (2008) 0.90
Infection in the bone marrow transplant recipient. Infect Dis Clin North Am (1995) 0.90
Lysis of varicella zoster virus infected cells by lymphocytes from normal humans and immunosuppressed pediatric leukaemic patients. Clin Exp Immunol (1985) 0.89
A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood (1993) 0.88
Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob Agents Chemother (1995) 0.87
Early detection and treatment of cytomegalovirus infections in marrow transplant patients: methodological aspects and implications for therapeutic interventions. Bone Marrow Transplant (1994) 0.87
Rapidly progressive cutaneous Rhizopus microsporus infection presenting as Fournier's gangrene in a patient with acute myelogenous leukemia. Transpl Infect Dis (2011) 0.87
Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility. J Clin Microbiol (2013) 0.86
Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy. J Clin Oncol (2000) 0.86
Effect of bovine non-agglutinating antibodies on the blood clearance of 131I-labelled Brucella abortus strain 45/20. Vet Microbiol (1987) 0.85
Diagnosis of cytomegalovirus pneumonia by the polymerase chain reaction with archived frozen lung tissue and bronchoalveolar lavage fluid. Am J Clin Pathol (1993) 0.85
Staphylococcus aureus bacteremia in the surgical patient: a prospective analysis of 73 postoperative patients who developed Staphylococcus aureus bacteremia at a tertiary care facility. J Am Coll Surg (2000) 0.85
The association of spinal retroflexion with limb anomalies. Teratology (1980) 0.84
Efficacy of cytomegalovirus immunoglobulin in marrow transplant recipients with cytomegalovirus pneumonia. J Infect Dis (1987) 0.82
Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. Antimicrob Agents Chemother (1993) 0.82
Hepatosplenic candidiasis--a contraindication to marrow transplantation? Blood (1994) 0.81
A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant (1996) 0.81
Quantification of cytomegalovirus in bronchoalveolar lavage fluid after allogeneic marrow transplantation by centrifugation culture. J Clin Microbiol (1992) 0.81
[Detection in bovine serum of non-agglutinating antibodies directed against occult antigens of Brucella abortus strain 19]. Rev Argent Microbiol (1985) 0.81
Direct detection of cytomegalovirus from bronchoalveolar lavage samples by using a rapid in situ DNA hybridization assay. J Clin Microbiol (1989) 0.80
Cytomegalovirus-induced hemorrhagic cystitis following bone marrow transplantation. Clin Infect Dis (1993) 0.80
Detection of antigenic fractions from Brucella abortus S45/20 which bind to non-agglutinating antibodies using electroblotting and enzyme-linked antibody probes. Vet Microbiol (1986) 0.80
Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. J Infect Dis (1995) 0.80
A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. Biol Blood Marrow Transplant (1998) 0.79
Prediction of cytomegalovirus pneumonia after marrow transplantation from cellular characteristics and cytomegalovirus culture of bronchoalveolar lavage fluid. Transplantation (1994) 0.79
Intravenous lipid dose and incidence of bacteremia and fungemia in patients undergoing bone marrow transplantation. Am J Clin Nutr (1998) 0.77
Reduced cellular immunity to varicella zoster virus during treatment for acute lymphoblastic leukemia of childhood: in vitro studies of possible mechanisms. J Clin Immunol (1986) 0.77
The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients. Bone Marrow Transplant (1987) 0.76
Use of the PATH Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia. Eur J Clin Microbiol Infect Dis (2007) 0.76
Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. Biol Blood Marrow Transplant (1999) 0.75
Histoplasmosis and subcutaneous nodules in a kidney transplant recipient: erythema nodosum versus fungal panniculitis. Transpl Infect Dis (2013) 0.75